HOME >> BIOLOGY >> NEWS
Drug-naive schizophrenia: The dopamine connection

Since the introduction of chlorpromazine in psychiatry in 1952, all antipsychotic drugs with proven efficacy have been dopamine (DA) D2 receptor antagonists. It has been suggested that positive schizophrenic symptoms (such as hallucinations) are associated with increased subcortical DA neurotransmission, and negative and cognitive symptoms with impaired mesocortical DA function. Studies on striatal D2 receptor densities in drug-naive schizophrenic patients have indicated that deviation in D2 density is larger among patients vs. controls, and although some patients have markedly elevated D2 levels, the D2 densities do not differ substantially at group level. Although DA neurotransmission in basal ganglia may be more important for motor functions rather than for emotions and behavioral symptoms, D2 binding studies have previously concentrated in the striatum, because there have been no suitable in vivo -ligands available for measuring extrastriatal D2 receptor binding. The aim of this study was to test the hypothesis that extrastriatal D2/3 density in temporal and cingulate cortex is lower among drug naive schizophrenic patients when compared with matched controls.

The results indicate that in drug-naive schizophrenic patients the extrastriatal dopamine D2/3 receptor density is markedly decreased. The authors also observed negative correlations between D2/3 receptor density and age among controls, and between D2/3 density and negative and general psychopathological symptom scores among patients. These results support the previous hypothesis on dysfunction of mesocortical dopamine function behind the cognitive and negative symptoms in schizophrenia.


'"/>

Contact: Aimee Midei
molecularpsychiatry@mednet.ucla.edu
310-206-6739
Molecular Psychiatry
12-May-2003


Page: 1

Related biology news :

1. Cognitive therapy for schizophrenia: Hope for those whom drugs havent helped
2. Vollum scientists find new form of dopamine transmission
3. How amphetamine affects the dopamine transporter
4. The dopamine receptor D1 gene and ADHD: A piece of the genetic puzzle?
5. Jefferson scientists show neural stem cells can become dopamine-making brain cells in laboratory
6. Molecule awakens and maintains neural connections
7. The Mediterranean connection: ecological effects of El Nio in the Northern hemisphere
8. OHSU researchers discover possible connection between infant hormone exposure, obesity
9. Gene essential for development of normal brain connections resulting from sensory input discovered
10. K-State professor examines connections between food, culture and psychology in new book
11. New study clarifies connection of brain and heart failure

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... anticipated to expand at a CAGR of 25.76% during ... diseases is the primary factor for the growth of ... report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global ... product, technology, application, and geography. The stem cell market ...
(Date:3/30/2017)... HONG KONG , March 30, 2017 ... developed a system for three-dimensional (3D) fingerprint identification by adopting ground ... technology into a new realm of speed and accuracy for use ... applications at an affordable cost. ... ...
(Date:3/27/2017)... CENTRE, N.Y. , March 27, 2017 /PRNewswire-USNewswire/ ... Healthcare Information and Management Systems Society (HIMSS) Analytics ... Outpatient EMR Adoption Model sm . In addition, ... 12% of U.S. hospitals using an electronic medical ... CHS for its high level of EMR usage ...
Breaking Biology News(10 mins):
(Date:6/22/2017)... Frederick, MD (PRWEB) , ... June 22, 2017 ... ... software solutions provider, announced the release of Limfinity® version 6.5, a content-packed update ... Limfinity® framework continue to gain a larger and more diverse base of customers ...
(Date:6/20/2017)... NEWTOWN SQUARE, Pa. , June 20, 2017 /PRNewswire/ ... technology, is pleased to announce the issuance of a ... treating gout or hyperuricemia by the U.S. Patent and ... Biotech Inc., a winner of the Buzz of Bio ... , is akin to developing non-drug approaches to ...
(Date:6/19/2017)... ... 2017 , ... EDETEK, Inc., a clinical technology company focused ... two new additions of its award-winning cloud-based platform CONFORM™: Information Hub and Clinical ... Annual Meeting in Chicago, IL, June 19-22, 2017. , “Modern clinical trials use ...
(Date:6/16/2017)... Rocky Hill, CT (PRWEB) , ... June 16, 2017 , ... ... of last night’s Entrepreneur Innovation Awards (EIA), held at The LOFT at Chelsea Piers ... their innovative project ideas to a panel of judges for an opportunity to secure ...
Breaking Biology Technology:
Cached News: